FDA Approved: ORSERDU — Supplemental Application (Stemline Therapeutics, Inc.)

View source ↗

Summary

The FDA approves a supplemental application for ORSERDU (elacestrant) submitted by Stemline Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Orserdu (Elacestrant)

Snippet

SUPPL AP for ORSERDU (ELACESTRANT)